Deepcell is pioneering new methods in single cell analysis by combining innovations in microfluidics, optics, and AI. The company leverages single cell morphology for deep characterization of cells.

Deepcell

Deepcell is involved in single cell analysis by combining innovations in microfluidics, optics, and AI to provide insights into cells’ phenotype and function.

Deepcell | 12,395 followers on LinkedIn. Deepcell is pioneering new methods in single cell analysis by combining innovations in microfluidics, optics, and AI. Through these multiple lenses, we are magnifying insights into cells’ phenotype and function to address important research questions across biology.

Don Kaiser

Biotech Tools & Life Sciences Operations • High-Impact Leadership • Company Building • Corporate Governance • Board Engagement • Business…

Kevin Farrell

Director, Global Field Service at Deepcell

Mike Addison

Quantitative Image Analysis

Cris Luengo

Have a Spooktacular Halloween—May Your Experiments Be Free of unidentified beings! #halloween #deepcell

🌟 Exciting News in the Fight Against Acute Myeloid Leukemia 🌟 Congratulations to Drs. Scott Manalis and Michael Hemann at Massachusetts Institute of Technology and Dr. Andrew Lane at Dana-Farber Cancer Institute (DFCI), for securing a groundbreaking NIH grant to leverage Deepcell technology in advancing acute myeloid leukemia (AML) research! 🎉 This powerful collaboration combines cutting-edge technology with clinical expertise to transform the treatment of minimal/measurable residual disease (MRD). Leveraging Deepcell’s high-content, label-free brightfield imaging and AI-powered sorting, the MIT and DFCI teams will work together to develop a novel platform targeting MRD with unprecedented precision. Their goal? To predict therapeutic response and identify patient-specific vulnerabilities in MRD before relapse, marking a significant step forward in the battle against AML. Together, we are empowering clinicians with real-time insights to shape the future of cancer care. Once again, congratulations to the team, and we can’t wait to see what’s next! 🌱

🔬 Unlocking the Complexity of Cell Death with High-Dimensional Morphology Data Using the REM-I platform, we've captured the intricate and dynamic process of cell death through high-dimensional morphology data. REM-I’s discriminative resolution allows us to identify subtle morphological shifts in the very early and mid-phases of apoptosis. By leveraging deep learning and computer vision, the platform provides orthogonal biological insights that not only complement but often surpass what traditional cytotechnology and protein-based biomarkers can reveal. Check out the visualizations below: (A) Morphology UMAP: Generated by REM-I and colored by cluster using the Leiden algorithm, with representative images included. These morphotype clusters align with morphological changes as cells undergo apoptosis and necrosis. (B) UMAP Visualization: Colored by population density, this visualization demonstrates how different treatments result in varying morphological expressions. Representative images from each treatment condition are displayed below. #Morpholomics #DeepLearning #ComputerVision #CellBiology #Apoptosis #Morphology #Deepcell

🔍 How can simply looking at cells through the Deepcell lens guide cancer therapy decisions? In collaboration with AbbVie (data presented at #AACR2024 ), we demonstrated direct linking between cell morphology to gene expression and function in a lung cancer patient tissue biopsy. 🔬 We identified a rare malignant subpopulation (Cluster 0) with a drastically different gene expression profile compared to the majority of the patient's cancer cells (Cluster 2). 💡 Through sorting, we uncovered key differences in gene expression and pathways, including upregulation of STAT3 (which promotes tumor growth, survival, angiogenesis, immune evasion, and inflammation) and NF-kB signaling (fueling inflammation, tumor survival, resistance to apoptosis, and metastasis) in this rare subpopulation. 🎯 These insights suggest therapeutically targeting STAT3 and NF-kB signaling to effectively combat Cluster 0. The results underscore #REM -I’s potential to unveil hidden cellular subtypes, drive groundbreaking cancer therapies, and transform patient outcomes. Start your journey to harness the power of AI for your application by requesting a demo here: https://lnkd.in/g_nPdRR4 Link to AACR poster here: https://lnkd.in/gF9zA-T4 #PrecisionOncology #CancerResearch #Deepcell #AACR2024 #CancerTherapies #Morpholomics

Congratulations to Deepcell’s scientific cofounder Prof. Euan Ashley for being appointed as the chair of Stanford Department of Medicine .

It is a pleasure to see groundbreaking applications of Deepcell's AI technology highlighted in the discussion organized by Rotterdam Square led by Prof. Peter J. van der Spek . From detecting small numbers of affected cells in blood and urine to enhancing diagnostics across fields like cardiology, oncology, and immunology, Deepcell's AI-enabled solutions continue to push the boundaries of personalized healthcare. "In the time it takes a pathologist to view ten cells and drink a cup of coffee, her AI-enabled colleague can scan up to 100,000 cells and compare them with an extensive library. " Interested to understand how our groundbreaking products can transform your clinical workflows? Reach out to us and request a demo: https://lnkd.in/g_nPdRR4

This is incredibly exciting! Will staining be obsolete in the near future? That's certainly what we are seeing with the #rem -i platform at Deepcell . The promise of label-free workflows holds promise for simplifying, streamlining and removing biases from clinical and drug development workflows. As frontiers in AI + high resolution brightfield imaging we are excited about these results and insights.

Maddison Masaeli

Truly, the natural world hath never been more within our grasp!

🧱 Builders w/ Maddison Masaeli - Co-Founder & CEO @ Deepcell 🚀 Excited to share our latest podcast episode featuring Maddison Masaeli, Co-founder & CEO of @Deepcell! In this insightful conversation, Maddison delves into Deepcell’s innovative approach to single-cell imaging and analysis, shedding light on their groundbreaking technology and its transformative impact on diagnostic testing and therapeutics. Discover how their ambitious project is building the world’s largest database of cellular morphologies and explore the future of precision medicine. Don’t miss this chance to gain valuable insights into the cutting-edge developments shaping the future of healthcare. 🎧 Tune in:

Metric
Company Name	Deepcell
Symbol
MSH ID	COM:DEEPCELL
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	deepcell.com
LinkedIn	deepcell
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DEEP

COM:DEEPCELL

Deepcell

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue